key: cord-0705902-8qfflm7d
authors: Gabor, Julian J.; Kreidenweiss, Andrea; Weber, Stefan; Salama, Moaaz; Sulyok, Mihaly; Sulyok, Zita; Koehne, Erik; Esen, Meral; Kreuels, Benno; Shamsrizi, Parichehr; Biecker, Erwin; Mordmüller, Benjamin; Berg, Christoph P.; Fusco, Stefano; Köhler, Carsten; Kubicka, Stefan; Leitlein, Jens; Addo, Marylyn; Ramharter, Michael; Schwab, Matthias; Bissinger, Alfred Lennart; Velavan, Thirumalaisamy P.; Krishna, Sanjeev; Kremsner, Peter G.
title: A call to caution when hydroxychloroquine is given to elderly COVID-19 patients
date: 2021-04-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.009
sha: 7605562e6843aaf1f3317cfd0f2436b148e497a7
doc_id: 705902
cord_uid: 8qfflm7d

Introduction Hydroxychloroquine use in COVID-19 patients was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk for hydroxychloroquine interactions with comorbidities and co-medications contributing to detrimental, including fatal adverse treatment effects. Methods This is a retrospective survey of health conditions and co-medications of COVID-19 patients who were pre-screened for enrolment into a randomized, double-blind, placebo-controlled hydroxychloroquine multicenter trial. Results Our survey involved 305 patients (median age 71 (IQR: 59-81) years). The majority of patients (N = 279, 92%) considered for inclusion into the clinical trial were not eligible mainly due to safety concerns caused by health conditions or co-medications. Most common were QT prolonging drugs (N = 188, 62%) and hematologic/hemato-oncologic diseases (N = 39, 13%) which prohibited the administration of hydroxychloroquine in our clinical trial. Additionally, 165 (54%) patients had health conditions and 167 (55%) were on co-medications that did not prohibit hydroxychloroquine treatment but had a risk of adverse interactions with hydroxychloroquine. Most common were diabetes (N = 86, 28%), renal insufficiency (N = 69, 23%) and heart failure (N = 58, 19%). Conclusion The majority of hospitalized COVID-19 patients had health conditions or took co-medications precluding safe treatment with hydroxychloroquine. Therefore, especially in elderly, hydroxychloroquine should be administered with extreme caution and only in clinical trials.

Hydroxychloroquine use in COVID-19 patients was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk for hydroxychloroquine interactions with comorbidities and co-medications contributing to detrimental, including fatal adverse treatment effects.

This is a retrospective survey of health conditions and co-medications of COVID-19 patients who were pre-screened for enrolment into a randomized, double-blind, placebo-controlled hydroxychloroquine multicenter trial.

Our survey involved 305 patients (median age 71 (IQR: 59-81) years). The majority of patients (N=279, 92%) considered for inclusion into the clinical trial were not eligible mainly due to safety concerns caused by health conditions or co-medications.

Most common were QT prolonging drugs (N=188, 62%) and hematologic/hemato-oncologic J o u r n a l P r e -p r o o f

The Coronavirus disease pandemic initiated an urgent search for safe, and effective treatments. Repurposing approved drugs for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, can save considerable effort, time and costs. (Krishna et al., 2020) These drugs must be suitable for use in elderly patients and those with underlying health conditions since those are especially threatened by severe disease and complications.

One of these drugs is hydroxychloroquine (HCQ), a less toxic and more effective derivative of chloroquine (CQ). (Liu et al., 2020; Yao et al., 2020) With many years of clinical experience, a well understood safety record, low cost of goods and promising anti-viral in vitro activity, HCQ seemed to be an ideal candidate for managing the COVID-19 pandemic. HCQ was J o u r n a l P r e -p r o o f added to the national treatment recommendations in China, the US (Gao and Hu, 2020; Lei et al., 2020) , France, India, Brazil and other countries. On 1 April 2020 the European Medicines Agency stated that HCQ should only be used in clinical trials or emergency use programs. (Lei et al., 2020) Until now, hospitalized patients suffering from COVID-19 have been regularly treated with HCQ, including in the European Union. HCQ has a narrow therapeutic range. Unfortunately, it has been given in varying doses sometimes reaching dangerous cumulative levels. Its assumed positive effect often led to a very optimistic risk-benefit assessment, even in the presence of underlying health conditions or concomitant medications.

Concerns about the efficacy and safety of HCQ were soon raised. (Rosenke et al., 2020) Unfavorable clinical courses, increased adverse effects and even higher mortality were discussed in public media, mostly due to known life threatening side effects of CQ and HCQ. (Borba et al., 2020) Most of these side effects (e.g. cardiac arrhythmias) and unfavorable outcomes occurred in patients with a more severe course of COVID-19 and underlying health conditions (Magagnoli et al., 2020; Rosenberg et al., 2020) and could have been avoided by a more conservative assessment of potential risks with regard to comorbidities and concomitant medications.

While conducting a multicenter placebo-controlled trial with HCQ in hospitalized COVID-19 patients, we encountered many obstacles to recruit patients. Most patients could not be enrolled into the trial due to co-medications or underlying health conditions interfering with safe HCQ administration.

In this survey, we aimed to determine in a representative population of hospitalized COVID- 

This is a retrospective evaluation of the medical records of hospitalized patients screened for eligibility for participation in a randomized, double-blind, HCQ-placebo controlled multicenter Phase II trial (Study Code: COV-HCQ, EudraCT-Number 2020-001224-33) to assess safety and efficacy of HCQ treatment in hospitalized COVID-19 patients. In brief, hospitalized adults with a positive SARS-COV-2 PCR were enrolled and received once daily HCQ for 7 days (800 mg at day 1 and 600 mg/day on day 2 to day 7) and were followed-up until virus clearance and for safety investigations. The study was conducted in Germany at the University Hospitals of Tübingen and Hamburg, and local hospitals in Balingen, Reutlingen, and Stuttgart. The COV-HCQ trial and the retrospective evaluation of medical reports were approved by the responsible ethics committees in Tübingen, Stuttgart and Hamburg. The clinical trial was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained for trial participation and only deidentified data were collected for the retrospective analysis.

After the retrospective data evaluation was approved by the local ethics committees, hospital electronic health records were searched, and deidentified COVID-19 patient data were collected of hospital stays from 27 March to 28 May 2020. Inclusion criteria for the retrospective evaluation were: adult, hospitalized patients and PCR confirmed SARS-CoV-2 infection via nasopharyngeal swab. The following variables were analyzed: age, date of SARS-CoV-2 PCR positive nasopharyngeal swab, concomitant medication, and underlying health conditions. Safety margins for HCQ administration in the COV-HCQ trial were pre-defined in the trial exclusion criteria adhering to SMPC (Sanofi, 2019) , the recommendation of the Fed- 

In total, 305 hospitalized SARS-CoV-2 infected patients were screened for eligibility to be enrolled in the COV-HCQ trial and formed part of this retrospective evaluation. Amongst the patients 178 (58%) were males. Median age was 71 years (IQR 59-81). Women (median: 73 years; IQR 61-83) were older than men (median: 69 years, IQR 58-80, p=0.046).

Of the screened patients, 252 (83%) could not be enrolled due to safety concerns caused by concomitant medications or different health conditions (Table) and 27 (9%) of screened patients refused informed consent.

Most frequent exclusion criteria (N=188, 62%) was intake of drugs that could prolong the QT interval and cause cardiac abnormalities ranging from concomitant intake of 1 to 6 QT prolonging drugs. Overall, 375 QT prolonging drug prescriptions were found as co-medications in this cohort. Other frequent trial exclusion criteria were intensive care unit treatment (N=47, 15%), hematologic or hemato-oncologic diseases (N=39, 13%), and dementia/ cognitive impairment (N=34, 11%) (Table) . Five patients already received HCQ as co-medication.

Additionally, 244 (80%) of all COVID-19 patients had medical conditions and/or took medications that are not strictly contraindicated but could be unfavorably affected by HCQ. Interfering health conditions were identified 267 times in a total of 165 (54%) patients. Most common were diabetes (N=86, 28%), renal insufficiency (N=69, 23%) and heart failure (N=58, 19%). Intake of concomitant medications other than QT prolonging drugs that can interact with HCQ was found in 167 (55%) patients. Number of trial exclusion criteria, interfering health conditions or co-medications increased by age (p<0.001). Taken together 279 (92 %) of the screened patients were not eligible mainly due to safety concerns caused by health conditions or concomitant medications.

This evaluation of medical conditions and co-medications that preclude safe HCQ administration focused on hospitalized COVID-19 patients in Germany. The majority were elderly patients with multiple underlying health conditions. Dementia and hematologic/hemato-oncological diseases were common comorbidities that did not allow trial inclusion. Other comorbidities like diabetes, renal insufficiency or heart failure were additional reasons to avoid HCQ treatment. These diseases are not only linked to the age of this cohort -that itself poses a risk of severe COVID-19 -but are also associated with a higher risk of an unfavorable COVID-19 clinical course.(National Center for Immunization and Respiratory Diseases (NCIRD), 2020) Co-medications are another obstacle to safe HCQ administration in elderly COVID-19 patients. Some adverse effects often may not be clinically significant but rarely can have severe consequences. When HCQ administration is considered, great attention should be given to prescribed concomitant QT interval prolonging drugs. Most of the screened patients took at least one QT prolonging drug amongst half of them even two or more. Cardiac J o u r n a l P r e -p r o o f arrhythmias due to QT prolongation and ventricular tachycardia in patients treated with CQ led to the stop of a trial in Brazil. (Borba et al., 2020) When national treatment recommendations suggested HCQ for COVID-19 treatment during the first pandemic wave, high numbers of patients were treated with HCQ on a regular basis and unfortunately screening for these known side effects was not always applied.

Data in a recent preprint of a meta-analysis including 28 randomized controlled trials investigating HCQ or CQ as treatment for COVID-19 showed a combined odds ratio (OR) on allcause mortality of 1.11 (95% CI:1.02-1.20) in the HCQ treated patients (Axfors et al., 2020) , which indicates a negative effect of HCQ in the study population. Results were mainly driven by the RECOVERY trial and the WHO SOLIDARITY trial which contributed 47% and 19% of the analyzed patients and had OR for mortality of 1.11 (95%CI 0.96-1.27) and 1.21 (95%CI; 0.89-1.63), respectively. In both trials very high doses of HCQ were used (800mg at hours 0 and 6; 400mg at hour 12 followed by 400mg every 12 hours -for 9 days in RECOVERY or for 10 days in SOLIDARITY) comparable to twice the maximum recommended daily dose and reaching levels of acute intoxication according to the SMPC. RECOVERY Collaborative Group et al., 2020; Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, 2021) Both trials included patients with comorbidities comparable to those in our COV-HCQ trial.

Recruitment rates of 67% (RECOVERY) and of 99% (SOLIDARITY) were much higher compared to 8% in our study. Respectively, mortality rates were 26% and 12% versus 3 % in our trial. (RECOVERY Collaborative Group et al., 2020; Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, 2021) In the meta-analysis, a subgroup of mostly yet unpublished, smaller, well conducted placebo-controlled trials showed a trend towards a benefit for HCQ treated patients with a lower mortality (OR 0.88, 95% CI:0.55-1.41) (Axfors 

The COV-HCQ trial and the retrospective evaluation of medical reports were approved by the responsible ethics committees in Tübingen, Stuttgart and Hamburg. The clinical trial was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained for trial participation and only deidentified data were collected for the retrospective analysis. 

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative metaanalysis of randomized trials

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease

Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

National Center for Immunization and Respiratory Diseases (NCIRD). Certain Medical Conditions and Risk for Severe COVID-19 Illness

Effect in Hospitalized Patients with Covid-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State

Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS -CoV-2. BioRxiv 2020

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Table: Trial exclusion criteria and medical conditions and concomitant medications unfavorable for HCQ intake

J o u r n a l P r e -p r o o f